AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 13.870-14.070 for the period, compared to the consensus estimate of 14.020. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ABBV shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. Canaccord Genuity Group increased their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Cantor Fitzgerald lifted their price target on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Piper Sandler upped their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.95.

AbbVie Trading Down 0.4%

ABBV opened at $260.69 on Friday. AbbVie has a 12 month low of $190.75 and a 12 month high of $267.47. The business’s 50-day moving average price is $254.57 and its 200-day moving average price is $229.87. The company has a market cap of $460.58 billion, a P/E ratio of 73.64, a P/E/G ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts forecast that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivered strong Phase 3 results. AbbVie said the CERVINO trial met both primary endpoints in relapsed or refractory multiple myeloma. The treatment produced a 74% objective response rate versus 45.7% for investigator-selected standard therapies and reduced the risk of disease progression or death by 60%. Its manageable safety profile and monthly dosing could support regulatory filing and eventual competition in the BCMA-targeted market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: The Apogee Therapeutics acquisition expands AbbVie’s immunology pipeline. The completed $10.9 billion transaction adds late-stage therapies including zumilokibart for atopic dermatitis and an IL-13/TSLP program for asthma, helping diversify growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Core growth products continue to offset Humira erosion. Recent coverage highlighted strong Skyrizi and Rinvoq growth, while technical commentary noted that ABBV has held above its 50-day and 200-day moving averages. Analysts maintain an overall “Moderate Buy” view, and the stock’s dividend-growth profile remains attractive to income-focused investors.
• Neutral Sentiment: Management reaffirmed its 2026 outlook. Adjusted EPS guidance remains $13.87–$14.07, with third-quarter guidance of $3.84–$3.88. The full-year range is broadly aligned with the $14.02 analyst consensus, offering limited incremental upside from the update.
• Negative Sentiment: Apogee is expected to weigh on near-term earnings. The acquisition broadens AbbVie’s pipeline but is expected to be dilutive initially and potentially accretive only around 2032, raising execution and return-on-investment concerns despite the long-term strategic benefits.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. boosted its stake in AbbVie by 38.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock valued at $5,906,000 after purchasing an additional 7,116 shares during the last quarter. Strive Financial Group LLC bought a new stake in shares of AbbVie in the fourth quarter worth approximately $216,000. Blue Sparrow LLC DE purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $28,561,000. Mercer Global Advisors Inc. ADV lifted its position in AbbVie by 5.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock valued at $100,411,000 after purchasing an additional 23,859 shares during the period. Finally, Summit Global Investments increased its position in shares of AbbVie by 21.4% during the 4th quarter. Summit Global Investments now owns 16,916 shares of the company’s stock valued at $3,865,000 after purchasing an additional 2,987 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.